Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience

Abstract Aims Heart failure with reduced ejection fraction (HFrEF) is associated with excessive sympathetic and impaired parasympathetic activity. The Barostim Neo™ device is used for electronical baroreflex activation therapy (BAT) to counteract autonomic nervous system dysbalance. Randomized trial...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Carola Blanco, Tomas Madej, Norman Mangner, Jennifer Hommel, Susanna Grimm, Michael Knaut, Axel Linke, Ephraim B. Winzer
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Oxford University Press 2023-12-01
Sarja:	ESC Heart Failure
Aiheet:	Chronic heart failure Device therapy Baroreflex activation therapy Barostim Neo™
Linkit:	https://doi.org/10.1002/ehf2.14508
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!